Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan: Outcomes of 1300 patients

Yorozu, Atsunori; Kuroiwa, Nobuko; Takahashi, A.; Toya, Kazuhito; Saito, Shiro; Nishiyama, Toru; Yagi, Yasuto; Tanaka, Tomohiko; Shiraishi, Yasuyuki; Ohashi, Toshio

doi:10.1016/j.brachy.2014.06.008

Cited by 46 publications

(54 citation statements)

References 34 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As an internal radiotherapy, 125 I permanent brachytherapy has been reported since 1940s, which has been successfully used in the treatment of prostate cancer, glioma, pancreatic cancer, hepatocellular carcinoma, and head and neck neoplasms 19–21,28,29. Recently, CT-guided 125 I seed implantation has been attempted to treat NSCLC 30.…”

Section: Discussionmentioning

confidence: 99%

<sup>125</sup>I brachytherapy of locally advanced non-small-cell lung cancer after one cycle of first-line chemotherapy：a comparison with best supportive care

Shen

Fan

Zhao

et al. 2017

OTT

View full text Add to dashboard Cite

ObjectivesThe objective of this study was to assess the efficacy of computed tomography (CT)-guided 125I brachytherapy alone in improving the survival and quality of life of patients with unresectable locally advanced non-small-cell lung cancer (NSCLC) after one cycle of first-line chemotherapy.Patients and methodsSixteen patients with locally advanced NSCLC were treated with CT-guided 125I brachytherapy after one cycle of first-line chemotherapy (group A). Sixteen patients who received only best supportive care (group B) were matched up with the patients in group A. Primary end point included survival, and secondary end point included assessment of safety, effectiveness of CT-guided 125I brachytherapy, and improvement in the quality of life.ResultsThe two groups were well balanced in terms of age, disease histology, tumor stage, tumor location, and performance status (P>0.05). The median follow-up time was 16 months (range, 3–30). The total tumor response rate was 75.0% in group A, which was significantly higher than that in group B (0.0%) (P<0.01). The median progression-free survival time was 4.80 months for patients in group A and 1.35 months for patients in group B (P<0.001). Kaplan–Meier survival analysis showed that the median survival time of group A was 9.4±0.3 months versus 8.4±0.1 months in group B (P=0.013). Tumor-related symptoms of patients were significantly relieved, and the quality of life was markedly improved in group A than in group B.ConclusionCT-guided 125I brachytherapy improved the survival of patients with locally advanced NSCLC and quality of life after one cycle of first-line chemotherapy compared with best supportive care.

show abstract

Section: Discussionmentioning

confidence: 99%

<sup>125</sup>I brachytherapy of locally advanced non-small-cell lung cancer after one cycle of first-line chemotherapy：a comparison with best supportive care

Shen

Fan

Zhao

et al. 2017

OTT

View full text Add to dashboard Cite

show abstract

“…Yorozu et al 38 reported that a permanent 125 I seed implantation treatment of prostate cancer is safe and efficient. Nag et al 39 found that 125 I brachytherapy was a safe and effective alternative to other locally ablative techniques, and that it can provide long-term local control.…”

Section: Discussionmentioning

confidence: 99%

125I Brachytherapy in Locally Advanced Non-Small Cell Lung Cancer after Progression of Concurrent Radiochemotherapy

Xiang

Zhang

2016

Brachytherapy

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

125I Brachytherapy in Locally Advanced Nonsmall Cell Lung Cancer After Progression of Concurrent Radiochemotherapy

Xiang

Liu

et al. 2015

Medicine

View full text Add to dashboard Cite

To investigate the safety and effectiveness of computed tomography (CT)-guided 125I seed implantation for locally advanced nonsmall cell lung cancer (NSCLC) after progression of concurrent radiochemotherapy (CCRT).We reviewed 78 locally advanced NSCLC patients who had each one cycle of first-line CCRT but had progressive disease identified from January 2006 to February 2015 at our institution. A total of 37 patients with 44 lesions received CT-guided percutaneous 125I seed implantation and second-line chemotherapy (group A), while 41 with 41 lesions received second-line chemotherapy (group B).Patients in group A and B received a total of 37 and 41 first cycle of CCRT treatment. The median follow-up was 19 (range 3–36) months. After the second treatment, the total response rate (RR) in tumor response accounted for 63.6% in group A, which was significantly higher than that of group B (41.5%) (P = 0.033). The median progression-free survival time (PFST) was 8.00 ± 1.09 months and 5.00 ± 0.64 months in groups A and B (P = 0.011). The 1-, 2-, and 3-year overall survival (OS) rates for group A were 56.8%, 16.2%, and 2.7%, respectively. For group B, OS rates were 36.6%, 9.8%, and 2.4%, respectively. The median OS time was 14.00 ± 1.82 months and 10.00 ± 1.37 months for groups A and B, respectively (P = 0.059). Similar toxicity reactions were found in both groups. Tumor-related clinical symptoms were significantly reduced and the patients’ quality of life was obviously improved.CT-guided 125I seed implantation proved to be potentially beneficial in treating localized advanced NSCLC; it achieved good local control rates and relieved clinical symptoms without increasing side effects.

show abstract

Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan: Outcomes of 1300 patients

Cited by 46 publications

References 34 publications

<sup>125</sup>I brachytherapy of locally advanced non-small-cell lung cancer after one cycle of first-line chemotherapy：a comparison with best supportive care

<sup>125</sup>I brachytherapy of locally advanced non-small-cell lung cancer after one cycle of first-line chemotherapy：a comparison with best supportive care

125I Brachytherapy in Locally Advanced Non-Small Cell Lung Cancer after Progression of Concurrent Radiochemotherapy

125I Brachytherapy in Locally Advanced Nonsmall Cell Lung Cancer After Progression of Concurrent Radiochemotherapy

Contact Info

Product

Resources

About

Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan: Outcomes of 1300 patients

Cited by 46 publications

References 34 publications

<sup>125</sup>I&nbsp;brachytherapy of locally advanced non-small-cell lung cancer after one cycle of first-line chemotherapy：a comparison with best supportive care

<sup>125</sup>I&nbsp;brachytherapy of locally advanced non-small-cell lung cancer after one cycle of first-line chemotherapy：a comparison with best supportive care

125I Brachytherapy in Locally Advanced Non-Small Cell Lung Cancer after Progression of Concurrent Radiochemotherapy

125I Brachytherapy in Locally Advanced Nonsmall Cell Lung Cancer After Progression of Concurrent Radiochemotherapy

Contact Info

Product

Resources

About

<sup>125</sup>I brachytherapy of locally advanced non-small-cell lung cancer after one cycle of first-line chemotherapy：a comparison with best supportive care

<sup>125</sup>I brachytherapy of locally advanced non-small-cell lung cancer after one cycle of first-line chemotherapy：a comparison with best supportive care